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Abstract
Background: Thrombolysis after acute ischemic stroke has only proven to be beneficial in a subset of patients. The
soluble recombinant analogue of human thrombomodulin, Solulin, was studied in an in vivo rat model of acute
ischemic stroke.
Methods: Male SD rats were subjected to 2 hrs of transient middle cerebral artery occlusion (tMCAO). Rats treated
with Solulin intravenously shortly before reperfusion were compared to rats receiving normal saline i.v. with respect
to infarct volumes, neurological deficits and mortality. Gene expression of IL-6, IL-1b, TNF-a, MMP-9, CD11B and
GFAP were semiquantitatively analyzed by rtPCR of the penumbra.
Results: 24 hrs after reperfusion, rats were neurologically tested, euthanized and infarct volumes determined.
Solulin significantly reduced mean total (p = 0.001), cortical (p = 0.002), and basal ganglia (p = 0.036) infarct
volumes. Hippocampal infarct volumes (p = 0.191) were not significantly affected. Solulin significantly
downregulated the expression of IL-1b (79%; p < 0.001), TNF-a (59%; p = 0.001), IL-6 (47%; p = 0.04), and CD11B
(49%; p = 0.001) in the infarcted cortex compared to controls.
Conclusions: Solulin reduced mean total, cortical and basal ganglia infarct volumes and regulated a subset of
cytokines and proteases after tMCAO suggesting the potency of this compound for therapeutic interventions.
Background
Stroke is a major cause of morbidity and mortality in
the Western civilization. Roughly 60% of ischemic
strokes are attributable to large-artery occlusion by
thrombembolism. Complete absence of perfusion results
in irreversible brain damage and neuronal loss in the
stroke core. However, the surrounding penumbra con-
tains functionally impaired, yet reversibly damaged neu-
rons which are potentially salvageable. The goal in
modern stroke therapy, therefore, is to protect the
penumbra. To date, the only approved drug for lysis
therapy is recombinant tissue plasminogen activator
(rtPA) which has shown significant benefit in patient
outcome when given up to 4.5 hours of onset. Less than
10% of all acute stroke patients are eligible for this treat-
ment. No clinical trial has been able to demonstrate
clear beneficial effects in respect to improvement of
short- or long-term outcome after anticoagulatory ther-
apy in acute ischemic stroke. Therefore, there is still a
need for safe anticoagulatory substances with sufficient
antithrombotic effectiveness and minimal risk of hemor-
rhagic side effects.
Thombomodulin (TM) is an endothelial cell trans-
membrane protein that acts as a thrombin receptor to
modulate coagulation and fibrinolysis [1] and mediates
anti-inflammatory effects [2]. Solulin (INN: sothrombo-
modulin alpha) is a recombinant soluble analogue of
human TM consisting of its extracellular domains and
distinguished by some point mutations to enhance its
resistance against proteases and oxidation [3]. Most of
TMs’s/Solulin’s known activities are dependent on bind-
ing of thrombin, the Solulin/thrombin complex
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activating Thrombin Activatable Fibrinolysis Inhibitor
(TAFI) and, at higher concentrations, the serine protease
activated protein C (APC) [4-6]. Activated APC with
protein S as a co-factor attenuates the clotting cascade
by digestion of activated clotting factors Va and VIIIa
and prevents generation of thrombin and, finally, fibrin
[7,8]. APC-mediated anticoagulant effects of Solulin
have been implicated in its ability to restore cerebral
flood flow and decrease infarct volume in a murine
model of photothrombotic stroke [9]. In addition, TM
displays a variety of anti-inflammatory and anti-apopto-
tic activities, mediated by APC and the lectin-like
domain of TM [10]. The latter involves binding to and
cleavage of HMGB1, a pro-inflammatory high mobility
group box protein [2]. It also involves actions through
pathways capable of dampening endothelial responses to
proinflammatory stimuli [11,12].
In addition, anti-inflammatory and anti-apoptotic
activities mediated by the lectin-like domain of TM are
also discussed [11,12], which has been reported to bind
and inhibit HMGB1, a pro-inflammatory high mobility
group box protein [2].
In this study we analyzed whether Solulin, besides its
known antithrombotic effects, exerts neuroprotective
effects under transient ischemic conditions. Primary out-
come parameter was infarct volume. Secondary outcome
parameters were neurological outcome, mortality,
hemorrhagic adverse events, and gene expression. A set
of pro-inflammatory cytokines and proteases and micro-
glial (CD11B) as well as astroglial (GFAP) markers were
analyzed in the penumbra after 2 hours of tMCAO.
Methods
Study drug
Solulin was provided by PAION Deutschland GmbH
(Aachen, Germany).
Animals and transient middle cerebral artery occlusion
(tMCAO) procedure
Research and animal care procedures were approved by
the Review Board for the Care of Animal Subjects of the
district government (LANUV (Landesamt für Natur,
Umwelt und Verbraucherschutz, Northrhine-Westfalia,
Germany)).
Male Sprague Dawley rats (250-280 g, Harlan Labora-
tories, Boxmeer, Netherlands; n = 10) were randomized
to group 1 (n = 5) = control group without treatment or
group 2 (n = 5) = treatment with 1 mg/kg body weight
(BW) Solulin i.v. in normal saline (injection volume 5
ml/kg BW). Previous preclinical in vivo studies in rats
yielded the best beneficial effect at doses from 0.1 to 1
mg/kg BW, which showed increasing anticoagulatory
efficacy but no adverse events like hemorrhagic transfor-
mation that would be anticipated due to bleeding time
prolongation at excessive doses. In this study, therefore,
we decided to treat rats with a Solulin dose of 1 mg/kg
BW.
Animals were held in macrolone cages (Ehret GmbH,
Emmendingen, Germany) in a pathogen-free environ-
ment with food and water available ad libitum. They
were subjected to 2 hrs of tMCAO using the intralum-
inal thread-occlusion technique as reported previously
[13]. Animals were anesthetized with an intraperitoneal
drug combination of 0.15 mg/kg BW Medetomidin [1
mg/ml] (Domitor®, Pfizer GmbH, Berlin, Germany), 2
mg/kg BW Midazolam [5 mg/ml] (Ratiopharm GmbH,
Ulm, Germany) and 0.005 mg/kg BW Fentanyl [0.05
mg/ml] (JANSSEN-CILAG GmbH, Neuss, Germany)
and maintained by an hourly intramuscular applicaton
of 0.1-0.15 ml of the drug combination while breathing
spontaneously. A small inguinal incision was made and
after dissection of the left femoral artery and vein, poly-
ethylene catheters were introduced for arterial blood gas
measurements and intravenous drug application. ECG-
needle electrodes were placed for continuous heart rate
monitoring.
The left common carotid artery (CCA), internal caro-
tid artery (ICA) and external carotid artery (ECA) were
exposed through a midline neck incision. ECA and CCA
were ligated proximally and the vagus nerve carefully
dissected from the ICA. A 0.1% poly-L-lysine [14]
coated 3-0 monofilament nylon suture (Hugo Sachs
Elektronik, Harvard Apparatus, GmbH, March-Hugstet-
ten, Germany) of 5 cm length was introduced through
the distal CCA into the ICA and advanced until a resis-
tance was felt indicating the bifurcation of anterior and
middle cerebral artery, thus sufficiently occluding the
MCA. Body temperature was maintained at 37-37.5°C
with a heating pad (Fine Science Tools GmbH, Heidel-
berg, Germany) during the entire surgical procedure. To
prevent bleeding, the exposed vessels were carefully
ligated and a suture was tightened around the filament.
The neck incision was closed aseptically, and animals
were returned to their heated cages. Vehicle (5 ml/kg
BW normal saline) or Solulin (1 mg/kg BW) in normal
saline was applied i.v. by bolus injection 110 min after
MCAO, i.e. 10 min before reperfusion (thread removal).
Animals underwent neurological and behavioral scoring
shortly before they were euthanized 24 hrs after
tMCAO.
To assure appropriate MCA occlusion, regional cere-
bral blood perfusion (rCBF) over the left MCA was per-
formed by laser-Doppler flowmetry (LDF). Through a
small midline incision a 2-mm non-invasive laser-Dop-
pler probe (PeriFlux System 5000, Type PF 5001, Peri-
med, Sweden) was placed on the animal’s skull
approximately 1-3 mm posterior to the bregma and 2-4
mm lateral to the midline. Baseline measurements were
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taken 10-15 minutes before tMCAO. Compared to base-
line LDF showed a reduction of rCBF by at least 60%
after MCAO [15]. There were no significant group
differences.
TTC-staining and measurement of infarct volume
Prior to brain dissection and mRNA extraction animals
were deeply anesthetized and perfused transcardially
with normal saline (0.9%) to wash out remaining circu-
lating blood cells within the brain. Rat brains were then
removed immediately, cut into 2 mm thick coronal sec-
tions using a rat brain matrix (Plastics One Inc., Roa-
noke, VA, USA) and stained in a 2% solution of 2,3,5-
triphenyltetrazolium chloride (TTC) in normal saline
(Bederson et al, 1986) at 37°C for 15 minutes. Vital tis-
sue stained deeply red while infarcted tissue did not
stain. Sections were then cryo-preserved. Images of the
TTC-stained sections were acquired (Sony DXC 390P,
Sony Germany GmbH). Total infarct volume as well as
separate assessment of cortex, basal ganglia and hippo-
campal infarct areas were determined by image analysis
software (Optimas 6.5, Adept Electronic Solutions Pty
Ltd., Sydney, Australia). Total infarct volume was calcu-
lated by a blinded investigator by adding all cross-sec-
tional areas multiplied by 2 mm (thickness of sections).
Edema correction of infarct volume was achieved using
the following equation [16]:
Vedi = Vinfarct ∗ (1 − (Vipsi − Vcontra)/Vcontra)
V infarct = Volume infarct, V ipsi = Volume ipsilateral
hemisphere, V contra = Volume contralateral hemisphere,
V edi = Volume edema corrected infarct
Assessment of neurological deficits
Before euthanization 24 hrs after tMCAO, neurological
testing was performed with a 6-point scale [17]. Assess-
ment was executed as follows:
5 = normal motor function, no neurological deficit, 4
= flexion of torso and contralateral forelimb when lifted
by the tail, 3 = decreased resistance to lateral push with-
out circling, 2 = circling to the contralateral side against
resistance when tugged by the tail on a flat surface, 1 =
circling spontaneously to the contralateral side, 0 = no
spontaneous motor activity, loss of walking or righting
reflex.
RNA isolation
On the basis of the TTC-staining results, total RNA was
isolated from cerebral cortex of the adjacent penumbra
regions of the infarcted hemispheres and the corre-
sponding regions of the contralateral hemispheres from
3 consecutive coronal sections of each brain (sections
2,3 and 4) with NucleoSpin®RNA II (MACHEREY-
NAGEL GmbH & Co. KG, Düren, Germany) according
to the manufacturers’ instructions.
Briefly, brain tissue was homogenized using Precellys
Keramik-Kit (PEQLAB Biotechnologie GMBH, Erlangen,
Germany) at 5000 × g for 15 s, cells were lysated with
b-mercaptoethanol, filtrated by centrifugation, washed in
70% ethanol, DNA was digested, RNA purified in several
washing steps and eluted in RNAse and DNAse free
ultra-pure water (Invitrogen GmbH, Darmstadt,
Germany).
Gene expression
RNA concentration and purity were assessed using
OD260/OD280 ratios (NanoDrop1000, PEQLAB Bio-
technologie GmbH, Erlangen, Germany) and gel electro-
phoresis under denaturation conditions. Reverse
transcription reactions were performed using M-MLV
RT-kit (Invitrogen GmbH, Darmstadt, Germany) and
random hexanucleotide primers. For gene expression
analysis, we studied transcription levels of following fac-
tors: IL-6 (interleukin-6), IL-1b (interleukin-1b), TNF-a
(tumor necrosis factor-a), MMP-9 (matrix metallopro-
teinase-9), CD11B and GFAP (glial fibrillary acidic pro-
tein) (all primers: Invitrogen GmbH, Darmstadt,
Germany). All primers were designed with free access
software (Primer3, Simgene.com). Primer sequences are
listed in table 1. Semiquantitative rtPCR was performed.
The amplified rtPCR products (10 μl) were electrophor-
etically separated on 1.5% agarose gels and stained with
ethidium bromide. Real-time rtPCR (RT-rtPCR) reac-
tions were carried out in a mixture consisting of 2 μl
cDNA, 2 μl RNAse-free water (Invitrogen GmbH,
Darmstadt, Germany), 5 μl 2×Sensi Mix × Plus SYBR &
Fluorescein Kit (Quantace, Bioline GmbH, Luckenwalde,
Germany) and 0.5 μl primers (10 pmol/μl). Reactions
were conducted in standard tubes using the MyiQ RT-
rtPCR detection system (Bio-Rad Laboratories, Munich,
Germany) under the following conditions: 10 min
Table 1 Oligonucleotide primers for RT-rtPCR
Gene Sense/Antisense Product size
HPRT s 5’-GGTCCATTCCTATGACTGTAGATTTT-3’
as 5’-CAATCAAGACGTTCTTTCCAGTT- 3’
125 bp
IL-6 s 5’-ACAGTGCATCATCGCTGTTC-3’
as 5’-CCGGAGAGGAGACTTCACAG-3’
160 bp
IL-1b s 5’-CTGTGACTCGTGGGATGATG-3’
as 5’-GGGATTTTGTCGTTGCTTGT-3’
209 bp
TNF-a s 5’-CTCCCAGAAAAGCAAGCAAC-3’
as 5’-CGAGCAGGAATGAGAAGAGG-3’
209 bp
MMP-9 s 5’-GTCCGGTTTCAGCATGTTTT-3’
as 5’-CCACCGAGCTATCCACTCAT-3’
158 bp
CD11B s 5’-TTACCGGACTGTGTGGACAA-3’
as 5’-AGTCTCCCACCACCAAAGTG-3’
239 bp
GFAP s 5’-AGAAAACCGCATCACCATT-3’
as 5’-GCACACCTCACATCACATCC-3’
187 bp
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enzyme activation at 95°C, 40 cycles of 15 s denatura-
tion at 95°C, 30 s annealing at individual temperatures,
30 s amplification at 72°C, and 5 s fluorescence mea-
surement at 72°C. External standard curves were gener-
ated by several fold dilutions of the target genes. The
concentrations of the target genes were calculated by
comparing Ct values in each sample with Ct values of
the internal standard curve. Melting curve analysis and
gel electrophoresis evaluation of the RT-rtPCR products
were routinely performed to determine the specificity of
the RT-rtPCR reaction. Gene expressions were normal-
ized to the mean expression values of the housekeeping
genes HPRT (hypoxanthine-guanine-phosphoribosyl-
transferase) and cyclophilin A.
Statistics
Sample size for the primary outcome parameter infarct
volume was calculated. From prior experiments mean
infarct volumes were expected around 300 mm3 ± 35
mm3 with an anticipated 30% reduction of infarct
volumes in the Solulin-treated cohort. The power was
set to b = 0.8 and the significance level to a = 0.05
yielding a calculated sample size of four animals per
group. In this study five animals per group were
included. Power calculation was performed using nQu-
ery Advisor® Version 7.0 (Statistical Solutions, Saugus,
Massachusetts, USA).
Edema corrected infarct volumes, and edema cor-
rected mean cortical, basal ganglia and hippocampal
infarct volumes were evaluated by two-way ANOVA.
Multiple comparisons (heart rate, blood gas measure-
ments and body temperature) were evaluated using an
unpaired t-test. Neuroscores and gene expression data
were evaluated by non-parametric Mann-Whitney-U-
test with SPSS software version 17.0 (SPSS Inc., Chi-
cago, IL, USA). All data are given as arithmetic means ±
SEM (standard error of the means), or as means ± SD
(standard deviation). P ≤ 0.05 was considered statisti-
cally significant. GraphPad PRISM® (GraphPad Software
Inc., La Jolla, CA, USA) was used to generate the
figures.
Results
Edema corrected Infarct volumes
Edema corrected total infarct volumes were assessed, as
well as infarct volumes separated for cortex, basal gang-
lia and hippocampus.
Brain edema formation in each group was determined
indirectly by use of the above mentioned formula [16].
Comparison of both groups revealed no significant dif-
ference in the extent of brain edema (p > 0.05).
A significant 27.4% reduction in mean total infarct
volumes was achieved in Solulin-treated compared to
vehicle-treated animals after tMCAO (Figure 1) (mean ±
SD; controls, 308.33 ± 33.41 mm3, n = 5; Solulin, 223.72
± 26 mm3, n = 5; p = 0.001). Similarly, significant
reductions of cortical (19%) (mean ± SEM; controls,
210.44 ± 10.21 mm3; Solulin, 171.21 ± 10.52 mm3; p =
0.002) and basal ganglia infarct volumes (12.6%) (con-
trols, 60.33 ± 3.66 mm3; Solulin, 52.08 ± 8.12 mm3; p =
0.036) could be detected. Hippocampal infarct sizes
were reduced (controls, 15.43 ± 1.94 mm3; Solulin, 0.75
± 0.75 mm3; p < 0.191) (Figure 2). However, this effect
was not statistically significant. These data suggest that
Solulin has a beneficial effect on the primary outcome
parameter with marked reduction of infarct volumes.
No hemorrhagic transformation was observed in either
group.
Figure 1 Edema corrected mean total infarct volumes after 2 h
of tMCAO 24 h post reperfusion. Edema corrected infarct
volumes (mm3) of Solulin-treated (left; n = 5) and vehicle-treated
animals (right; n = 5). Significant reduction of infarct volumes in the
Solulin-treated group (p = 0.001). Values are given as means ± SD.
Figure 2 Edema corrected mean cortical, basal ganglia and
hippocampal infarct volumes after 2 h of tMCAO 24 h post
reperfusion. A significant reduction of cortical (p = 0.002) and basal
ganglia (p = 0.036) infarct volumes was achieved. Hippocampal
infarct volumes were nominally but not statistically significantly
reduced. Values are given as means ± SEM.
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Monitoring
Heart rate and body temperature did not differ between
the groups. All blood gas measurements (pH, pO2,
pCO2, cNa
+ or cK+) before and during ischemia or after
reperfusion were comparable between the groups.
Neurological deficit
Neurological deficits in both groups were equally dis-
tributed. Four animals had a score of 2 (circling against
resistance) and one animal had a score of 1 (sponta-
neous circling) in each group, respectively.
Quantitative gene expression
HPRT and cyclophilin A served as a housekeeping gene
to normalize gene expressions of brain tissue samples
[18]. Gene expressions were semiquantitatively mea-
sured by RT-rtPCR using SYBR-Green (Quantace, Bio-
line GmbH, Luckenwalde, Germany) as intercalating
dye. This technique is frequently used to determine
gene expression levels. Values of the non-infarcted
hemisphere of the vehicle-treated group were set to
100%. All other values (infarcted brain half vehicle-trea-
ted group, infarcted and non-infarcted hemisphere of
the Solulin cohort) were expressed as percentages of the
latter (Figure 3, table 2).
A significant downregulation of IL-1b (79%; p <
0.001), TNF-a (59%; p = 0.001), IL-6 (47%; p = 0.04),
and CD11B (49%; p = 0.001) was found in Solulin-trea-
ted infarcted hemispheres compared to untreated
infarcted brain halves. Also MMP-9 (22%; p = 0.34) was
nominally reduced, but the difference was not statisti-
cally significant. In the non-infarcted Solulin-treated
hemispheres compared to untreated non-infarcted brain
halves, gene expression was significantly lower for IL-1b
(57%; p < 0.004) but not for TNF-a (p = 0.61), IL-6 (p
= 0.063), MMP-9 (p = 0.11) and CD11B (p = 0.34).
No significant difference could be detected in GFAP
(glial fibrillary acidic protein) expression neither
between injured (p = 0.094) nor between non-injured
hemispheres (p = 0.19) in both groups.
Discussion
Solulin administration caused a down-regulation of the
expression of inflammatory cytokines in the penumbra.
In particular, TNF-a, IL-1b, and IL-6 were regulated. In
addition, we observed that the expression of CD11B, a
marker for microglia/macrophage activation, was also
significantly reduced in Solulin-treated ischemic animals
compared to untreated infarcted controls. GFAP, an
astroglia marker, and MMP-9 were not regulated by
Solulin. Solulin achieved a significant reduction in mean
total infarct volumes (27.4%) with effective protection of
both cerebral cortex (19%) and basal ganglia (12.6%).
The overall reduction of infarct volumes does not suffice
Figure 3 Gene expression of IL-1b, IL-6, TNF-a, CD11B, MMP-9
and GFAP after 2 h of tMCAO 24 h post reperfusion. Gene
expression of IL-1b, IL-6, TNF-a, CD11B, MMP-9 and GFAP of 3
consecutive coronal sections of TTC-stained hemispheres. The
contralateral non-infarcted hemispheres of the vehicle-treated group
acted as internal controls. Values of these hemispheres were
therefore set to 100%. All other values (infarcted hemisphere
vehicle-treated group, infarcted and non-infarcted hemisphere of
the Solulin cohort) were expressed as percentages of the latter. RT-
PCR values were normalized to the housekeeping genes HPRT and
cyclophilin A. All mRNA levels are given as means ± SEM.
Table 2 Gene expression of IL-1b, IL-6, TNF-a, CD11B,
MMP-9 and GFAP after 2 h of tMCAO and 24 h post-
reperfusion
Vehicle Solulin
Gene Contralateral
[%]
Ipsilateral [%] Contralateral
[%]
Ipsilateral
[%]
IL-1b 100 1165.5 ±
1522.1
46.6 ± 42.8 242.7 ±
443.4
IL-6 100 775.2 ± 724.4 26.1 ± 22.2 411.7 ±
550.6
TNF-a 100 206.2 ± 278.9 86.1 ± 92.4 83.9 ± 56.9
MMP-
9
100 257.6 ± 131.1 41.9 ± 46.5 201.6 ± 97.1
CD11B 100 236.2 ± 56.1 86.6 ± 85.5 119.6 ±
102.8
GFAP 100 108.4 ± 69.5 71.7 ± 89.7 87.1 ± 89.7
Gene expression of three consecutive coronal sections of TTC-stained
hemispheres. The contralateral non-infarcted hemispheres of the vehicle-
treated group acted as internal controls. Values of these hemispheres were
therefore set to 100%. All other values (infarcted hemisphere vehicle-treated
group, infarcted and non-infarcted hemisphere of the Solulin cohort) were
expressed as percentages of the latter. RT-PCR values were normalized to the
housekeeping gene HPRT and cyclophilin A. All mRNA levels are given as
means ± SD.
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to explain the disparate decreases in expression of the
various pro-inflammatory cytokines (IL 1b, 79%; TNF-a,
59%; IL-6, 47%).
Cerebral ischemia triggers a pathogenic cascade in
which microglia are locally attracted and activated and
express growth factors, chemokines, and regulatory
inflammatory cytokines as mediators that attract mono-
nuclear cells and granulocytes which further damage the
ischemic brain tissue and its penumbra [19]. The mainly
proinflammatory cytokines TNF-a and IL-1b may
induce migration of neutrophils and macrophages into
the CNS [20]. The up-regulation of both cytokines has
often been demonstrated in transient and permanent
MCAO which suggests that these cytokines play an
important role in the inflammatory response associated
with focal ischemia [20,21].
TNF-a serves as a marker for activation of microglia
and macrophages during cerebral ischemia and other
inflammatory reactions as reported previously [22] and
appears to mediate cell death. Consistently, it was
demonstrated that the administration of TNF-a antibo-
dies or TNF-a binding receptors led to a reduction of
infarct volumes in experimental animal stroke models
[23,24]. Other studies, however, emphasize the neuro-
protective potency of TNF-a with a role during repair
and regeneration of brain tissue [25], making TNF-a
another example of the time-dependent duality of cer-
tain inflammatory molecules, being destructive at the
beginning while inducing an isochronic coordination of
protective mechanisms. IL-1b expression, like TNF-a,
seems to promote infarction progression in animal mod-
els of ischemic stroke [25]. Clausen and collaborators
demonstrated that IL-1b mRNA and TNF-a mRNA,
and TNF-a protein are produced by CD11b+ microglia/
macrophages in the penumbra as well as the core of
brain infarction [25]. CD11B is also expressed by imma-
ture dendritic cells of probably myeloid origin during
neuroinflammation after brain infarction which may be
associated with phagocytosis [26]. Its downregulation
might involve a decreased degradation reaction by den-
dritic cells and a decreased activation of microglia and
macrophages post-infarction, in turn leading to a
decreased expression of TNF-a and IL-1b. IL-6 mRNA
is produced during inflammatory processes of the CNS
[27] and is up-regulated after pMCAO in rats [28]; how-
ever, its role in both acute and chronic brain damage is
still unclear [29]. Whether its up-regulation is indicative
of neuronal damage or neural regeneration is still uncer-
tain [30].
There was no difference in expression of glial fibrillary
acidic protein (GFAP), neither in infarcted nor in the
unaffected hemispheres of both Solulin and control rats.
GFAP is the principal intermediate filament in mature
astrocytes and serves as a marker for reactive
astrogliosis [30,31] after nervous tissue injury. Since tis-
sue evaluation was done 24 hrs after tMCAO, the post-
operative time span appears too short for a significant
activation/proliferation of astrocytes. Thus, an increased
GFAP-expression was not anticipated in our study.
Matrix metalloproteinases (MMP) are proteases
related to extracellular matrix breakdown [32] inducing
neuronal damage, blood-brain-barrier (BBB) disruption
and rarely intracerebral hemorrhage. Degradation of the
basal lamina and tight junctions of cerebral blood ves-
sels leads to BBB disruption followed by formation of
cytotoxic as well as vasogenic brain edema and consecu-
tive apoptosis of neurons and oligodendrocytes [33].
MMPs might also play a role in abetting neutrophil and
macrophage invasion [34]. MMP-9 is not expressed in
the CNS but seems to invade the brain together with
leukocyte infiltration induced by focal ischemia [35,36].
Together with platelet-derived growth factor CC [9],
MMP-9 has been involved in BBB breakdown after
stroke [35,37].
As cerebral reperfusion in the current study was pro-
duced by removal of the occluding thread, it appears
unlikely that anticoagulation is central to Solulin’s ability
to reduce infarct volumes. Rather, its anti-inflammatory
and anti-apoptotic activities, mediated by its lectin-like
domain [11,12] and/or corresponding effects of APC
[38] seem to be involved. Antibodies against HMGB1
have been found to ameliorate brain infarction induced
by transient ischemia in rats, with inhibition of the
expression of TNFa, but practically no effect on cerebral
blood flow [20].
Nonetheless, there may also be a role for anticoagu-
lation, as restoring blood flow may give rise to down-
stream displacement of material formed around the
occluding suture. Solulin might also act to restore
blood flow in the dependent microvasculature, which
is likely to get clogged to some extent during the
ischemia period and will not readily re-open once the
occluding thread has been removed. This possibility is
supported by the observation that Solulin, in the
mouse photothrombotic model, was able to restore
blood flow when administered 30 or 60 min post-
occlusion [9]. From a different perspective, anti-inflam-
matory effects of Solulin may contribute to its benefi-
cial effects in the mouse photothrombotic model:
When administered 60 min after photothrombotic
occlusion, Solulin only transiently restored blood flow,
but was still able to cause a significant reduction of
infarct size 24 hrs later [9]. Thus, anti-inflammatory
and anticoagulant (profibrinolytic) effects of Solulin
may act in concert. As inflammation is a powerful pro-
coagulant/antifibrinolytic force [39], this profile would
make Solulin a promising tool in the setting of acute
cerebral ischemia.
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Conclusion
In response to the treatment with the recombinant solu-
ble analogue of the human transmembrane protein
thrombomodulin, Solulin, we could clearly demonstrate
a significant reduction in mean total infarct volumes as
well as of cortical and basal ganglia infarct volumes in a
model of transient focal cerebral ischemia. We could
further show that Solulin abolishes the induction of
TNF-a, IL-1b, IL-6, CD11B as well as of MMP-9 in the
penumbra. The underlying mechanisms of action are
not yet fully understood, but seem to involve anti-
inflammatory effects, possibly aided by activation of pro-
tein C and anticoagulant (profibrinolytic) effects. Requi-
site to understanding how this promising substance
brings about the profound reduction infarct volumes,
future neurocognitive studies are indicated.
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